Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Rating Upgraded by ValuEngine

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Friday, September 1st.

A number of other brokerages have also issued reports on TNXP. Aegis assumed coverage on shares of Tonix Pharmaceuticals Holding Corp. in a research note on Monday, June 26th. They set a “buy” rating and a $10.00 target price for the company. Dawson James restated a “buy” rating and set a $9.00 price target on shares of Tonix Pharmaceuticals Holding Corp. in a report on Wednesday, August 23rd. Drexel Hamilton began coverage on shares of Tonix Pharmaceuticals Holding Corp. in a report on Tuesday, August 22nd. They set a “buy” rating on the stock. Finally, Roth Capital upgraded shares of Tonix Pharmaceuticals Holding Corp. from a “neutral” rating to a “buy” rating and set a $6.00 target price on the stock in a report on Friday, August 18th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. Tonix Pharmaceuticals Holding Corp. has an average rating of “Buy” and a consensus price target of $8.33.

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) opened at 4.19 on Friday. Tonix Pharmaceuticals Holding Corp. has a 52 week low of $0.33 and a 52 week high of $9.40. The stock has a 50 day moving average price of $3.64 and a 200-day moving average price of $3.74. The firm’s market capitalization is $31.46 million.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last issued its earnings results on Monday, August 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.13. Equities analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post ($3.02) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Rating Upgraded by ValuEngine” was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://ledgergazette.com/2017/09/17/tonix-pharmaceuticals-holding-corp-tnxp-upgraded-to-sell-at-valuengine.html.

In related news, Director Ernest Mario sold 6,105 shares of the business’s stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $4.28, for a total transaction of $26,129.40. Following the completion of the sale, the director now directly owns 63,073 shares of the company’s stock, valued at $269,952.44. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Seth Lederman bought 20,000 shares of the stock in a transaction on Thursday, August 17th. The stock was purchased at an average cost of $3.00 per share, with a total value of $60,000.00. Following the purchase, the chief executive officer now directly owns 11,166 shares of the company’s stock, valued at approximately $33,498. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 50,000 shares of company stock worth $188,050. Company insiders own 4.00% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in TNXP. Renaissance Technologies LLC boosted its holdings in shares of Tonix Pharmaceuticals Holding Corp. by 108.4% in the fourth quarter. Renaissance Technologies LLC now owns 774,603 shares of the company’s stock valued at $364,000 after buying an additional 402,898 shares during the period. Dialectic Capital Management LP acquired a new position in shares of Tonix Pharmaceuticals Holding Corp. in the first quarter valued at approximately $187,000. Citadel Advisors LLC acquired a new position in shares of Tonix Pharmaceuticals Holding Corp. in the first quarter valued at approximately $119,000. Vanguard Group Inc. boosted its holdings in shares of Tonix Pharmaceuticals Holding Corp. by 28.8% in the second quarter. Vanguard Group Inc. now owns 184,377 shares of the company’s stock valued at $799,000 after buying an additional 41,264 shares during the period. Finally, B. Riley Financial Inc. acquired a new position in shares of Tonix Pharmaceuticals Holding Corp. in the second quarter valued at approximately $1,637,000. Institutional investors own 28.80% of the company’s stock.

Tonix Pharmaceuticals Holding Corp. Company Profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply